160 likes | 265 Views
Implications of C. difficile diagnostic testing. Not seeing the wood for the trees Warren Lowman Pathlink / Vermaak & Partners Pathologists Wits Donald Gordon Medical Centre Clinical Microbiology & Infectious Diseases, University of the Witwatersrand. Pubmed & C. difficile. 9298 hits
E N D
Implications of C. difficile diagnostic testing Not seeing the wood for the trees Warren Lowman Pathlink/ Vermaak & Partners Pathologists Wits Donald Gordon Medical Centre Clinical Microbiology & Infectious Diseases, University of the Witwatersrand
Pubmed & C. difficile • 9298 hits • + Clinical trials = 330 • + Diagnosis = 169 • + Testing = 20
Clinical relevance… 2 key issues that are largely ignored: • Pre-test probability • PPV
Are we selecting accurately? 67.1 tests/ 10 000 pt bed days (range, 29 – 153)
C. difficile diagnostics… • We are floundering- survey of UK labs indicate >25 different algorithms • Multitude of different assays • Impacts on our understanding of the epidemiology of CDI.
The “best” study Lancet Infect Dis 2013 Diagnostic assays Study design Clinical data
Salient points • Tested all faecal samples irrespective of request • Wide scope of practice • Detection of 3 targets: bacterium; toxin; gene • Predefined groups: diagnostic; severity • Statistically very “sound” • Diagnostic performance assessed in training phase
Clinical relevance by assay • Data for 6522 inpatient episodes
…clinical relevance by assay • Same comparison using PCR as surrogate for cytotoxigenic culture
The implications CLINICAL OUTCOME MANAGEMENT TOXIN POSITIVITY DIAGNOSTIC ASSAY
C. difficile excretors…an issue? Overtreatment…excessive antibiotic use! Cost…this all adds up
3-stage algorithm Not CDAD GDH CDAD EIA Toxin 8% NAAT Not CDAD C. difficile excretor